Medication info
Esomeprazole Magnesium Trihydrate 20 mg Tablet

Esomeprazole Magnesium Trihydrate 20 mg Tablet

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›21.69mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Pale pink, oblong film-coated tablet
Packaging
28 tablets/box [7 tablets/Alu-Alu x 4]
Approval status
Active

MFDS item code 201902217 · Approved 2019.04.11 · Insurance code 670501580

Summary

Main use
Treatment and prevention of gastroesophageal reflux, gastrointestinal disorders (e.g., ulcers and eradication therapy), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This drug should be swallowed with a liquid such as water and must not be chewed or crushed. 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have improved, subsequent symptoms should be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use, as-needed use is not recommended to control recurring symptoms. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg concomitantly with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with use of nonsteroidal anti-inflammatory drugs (COX-2 nonselective or selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical studies lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because experience in patients with severe renal failure is limited. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed 20 mg of this drug. Older adults: No dose adjustment is necessary.
Children's dosage
Adolescents 12 years of age and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents 12 years of age and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Adolescents 12 years of age and older — Once symptoms have improved, subsequent symptoms should be controlled by administering 20 mg once daily. Adolescents 12 years of age and older — In adults, 20 mg may be administered once daily as needed. For patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use, as-needed use is not recommended to control recurring symptoms. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment and prevention of gastroesophageal reflux, gastrointestinal disorders (e.g., ulcers and eradication therapy), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive reflux esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal symptoms
  • pain
  • discomfort
  • burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
View approved original text

This medication is used for the treatment of gastroesophageal reflux disease and erosive reflux esophagitis, and is effective as a long-term maintenance therapy for the prevention of recurrence in patients with esophagitis. It also helps improve symptoms of gastroesophageal reflux disease without esophagitis. It is used as part of a combination therapy with antibiotics to treat Helicobacter pylori infection, contributing to the treatment and prevention of recurrence of duodenal ulcers and peptic ulcers. It is also effective in treating and preventing upper gastrointestinal symptoms and ulcers caused by non-steroidal anti-inflammatory drugs. It is used for the treatment of Zollinger-Ellison syndrome and for the prevention and maintenance therapy of rebleeding from gastric or duodenal ulcers. Overall, it is a very useful medication for the treatment and symptom relief of gastrointestinal disorders.

Dosage and Administration

Adult dosage

This drug should be swallowed with a liquid such as water and must not be chewed or crushed. 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. · Once symptoms have improved, subsequent symptoms should be controlled by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. For patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use, as-needed use is not recommended to control recurring symptoms. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this drug 20 mg concomitantly with amoxicillin 1 g and clarithromycin 500 mg, twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, heartburn) associated with use of nonsteroidal anti-inflammatory drugs (COX-2 nonselective or selective) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Clinical studies lasting longer than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment duration is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with doses of 80 ∼ 160 mg per day. Doses greater than 80 mg per day should be divided into 2 doses. 6) Maintenance therapy following induction of prevention of rebleeding from gastric or duodenal ulcers by intravenous administration Administer 40 mg once daily for 4 weeks following intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. Renal impairment: No dose adjustment is necessary. Use with caution because experience in patients with severe renal failure is limited. Hepatic impairment: No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, do not exceed 20 mg of this drug. Older adults: No dose adjustment is necessary.

Children's dosage

Adolescents 12 years of age and older — Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. For patients whose esophagitis has not healed or whose symptoms persist, continue treatment for an additional 4 weeks. Adolescents 12 years of age and older — Symptomatic treatment of gastroesophageal reflux disease without esophagitis: 20 mg once daily. If symptoms are not controlled after 4 weeks, further evaluation is necessary. Adolescents 12 years of age and older — Once symptoms have improved, subsequent symptoms should be controlled by administering 20 mg once daily. Adolescents 12 years of age and older — In adults, 20 mg may be administered once daily as needed. For patients at high risk of gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug use, as-needed use is not recommended to control recurring symptoms. Children under 12 years of age: There is no experience with administration of this drug to children under 12 years of age.

Precautions

This drug should not be administered to patients with known allergies to certain ingredients or a history of hypersensitivity. It should also not be given to patients with allergies to penicillin or macrolide antibiotics, patients taking certain heart medications, nursing women, patients with a history of myocardial infarction, and those taking certain antiviral medications. This medication contains a dye called Yellow No. 5, and should be used with caution in patients with allergies or hypersensitivity to this ingredient. Various side effects, such as headache, dizziness, abdominal pain, diarrhea, nausea, and skin rash, may occur during treatment; therefore, patients should consult a doctor immediately if they experience any unusual symptoms. Long-term use may lead to hypomagnesemia, increased risk of fractures, and higher susceptibility to gastrointestinal infections; regular monitoring is recommended. This drug inhibits stomach acid secretion, which may interact with other medications, especially antiviral agents, anticoagulants, and anticonvulsants; caution is necessary when using in combination. The safety of this drug during pregnancy has not been sufficiently established, so it should be used only when necessary and under a doctor's supervision; it is recommended that nursing women do not take this medication. In cases of overdose, there is no specific antidote; symptomatic treatment is required and it should be stored out of reach of children. Additionally, transferring medications to other containers may cause accidents or degradation of quality, so caution is advised.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucinations, headache, dizziness, sensory disturbances, drowsiness, taste disorders, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distension, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, itching, rash, urticaria, hair loss, photosensitivity, polymorphous erythema, mucous membrane disorder syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, renal interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial edema, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, lethargy, pain, rigidity, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal hypoplasia, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue edema, ulcerative stomatitis, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, nosebleed, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, abnormal liver function, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, polydipsia, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatoid polymyalgia, loss of appetite, apathy, increased appetite, confusion, exacerbation of depression, hypertonia, sensory impairment, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorder, tremors, visual field defects, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal itching, erythematous rash, papular rash, otitis media, abnormal olfaction, loss of taste, taste dysgeusia, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, frequency of urination, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric zollinger-pollock, hypocalcemia, hypokalemia, rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture and should be stored in a tightly sealed container. The storage temperature should be kept between 1°C and 30°C at room temperature to maintain the drug's efficacy for a longer duration.

Appearance and packaging

Appearance

Pale pink, oblong film-coated tablet

Package unit

28 tablets/box [7 tablets/Alu-Alu x 4]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.